Cancer immunotherapies (Aduro BioTech)

N/A

Report date: 2022/10/25 20:00:47

Base Information

Drug NameCancer immunotherapies (Aduro BioTech)
Drug Alias NameTumour-cell-vaccine-GVAX - Aduro BioTechCancer immunotherapiesGVAX PancreasGVAX ProstateGVAX Leukemia +[7] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiosante Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAduro Biotech IncTakeda Pharmaceutical Co Ltd
Inactive CompaniesBiosante Pharmaceuticals IncBenaroya Research InstituteNational Cancer Institute
Active IndicationsPancreatic Neoplasms
Inactive IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A